Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-226.84%
operating margin TTM
-240.92%
revenue TTM
1.52 Million
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -2.35 |
| peg ratio | -0.19 |
| price to book ratio | 1.23 |
| price to sales ratio | 6.03 |
| enterprise value multiple | -2.88 |
| price fair value | 1.23 |
profitability ratios | |
|---|---|
| gross profit margin | 17.93% |
| operating profit margin | -240.92% |
| pretax profit margin | -228.57% |
| net profit margin | -226.84% |
| return on assets | -40.88% |
| return on equity | -50.77% |
| return on capital employed | -50.16% |
liquidity ratio | |
|---|---|
| current ratio | 3.74 |
| quick ratio | 3.31 |
| cash ratio | 0.95 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 139.66 |
| operating cycle | 293.92 |
| days of payables outstanding | 74.57 |
| cash conversion cycle | 219.35 |
| receivables turnover | 2.37 |
| payables turnover | 4.89 |
| inventory turnover | 2.61 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.06 |
| debt equity ratio | 0.08 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.08 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -6.06 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.26 |
| cash per share | 1.12 |
| operating cash flow per share | -1.22 |
| free cash flow operating cash flow ratio | 1.03 |
| cash flow coverage ratios | -6.06 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -31.89 |
Frequently Asked Questions
When was the last time Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported earnings?
Iovance Biotherapeutics, Inc. (IOVA) published its most recent earnings results on 07-11-2024.
What is Iovance Biotherapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)'s trailing twelve months ROE is -50.77%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Iovance Biotherapeutics, Inc. (IOVA) currently has a ROA of -40.88%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did IOVA's net profit margin stand at?
IOVA reported a profit margin of -226.84% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is IOVA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 3.74 in the most recent quarter. The quick ratio stood at 3.31, with a Debt/Eq ratio of 0.08.